Search

everythinglearnresearchcommunity

for

Search:↓

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.

Topical JAK inhibitors may help children with alopecia areata regrow hair.

Dupilumab for atopic dermatitis can cause mild skin issues in some patients.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Tislelizumab can cause cutaneous lupus erythematosus.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Pentoxifylline is a safe and effective alternative to triamcinolone acetonide for treating localized alopecia areata.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.

Abrocitinib may effectively treat stubborn alopecia universalis.

Infliximab may cause hair loss in Crohn's disease patients.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.